Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Director comp.
Senti Biosciences, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
08/11/2023 8-K Quarterly results
08/10/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/10/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/10/2023 8-K Asset disposition
Docs: "Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners – Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies –"
05/09/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/09/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Senti Bio Announces First Quarter 2023 Results and Pipeline Updates – New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy&#59; remains on track for IND submission and clearance in 2H 2023 –"
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/22/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/22/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/22/2023 10-K Annual Report for the period ended December 31, 2022
03/22/2023 8-K Quarterly results
Docs: "Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights - SENTI-202 on track to submit an Investigational New Drug application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS -"
02/14/2023 SC 13G PRICE T ROWE ASSOCIATES INC reports a 8.1% stake in Senti Biosciences Inc
02/14/2023 SC 13G/A Sculptor Capital LP reports a 0% stake in SENTI BIOSCIENCES INC
02/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A MORGAN STANLEY reports a 0.6% stake in Senti Biosciences, Inc.
02/08/2023 SC 13G Lonsdale Joe reports a 5.8% stake in Senti Biosciences, Inc.
01/27/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
01/27/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
01/27/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies&#59; Updates Cash Runway Guidance – R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other CEA-positive solid tumors –",
"CORPORATE PRESENTATION"
01/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "PRESENTATION"
09/30/2022 8-K Quarterly results
09/30/2022 EFFECT Form EFFECT - Notice of Effectiveness:
09/29/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy